Spots Global Cancer Trial Database for allogeneic stem cell transplantation
Every month we try and update this database with for allogeneic stem cell transplantation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS | NCT00396968 | Acute Myelogeno... Myelodysplastic... | AMD3100 Allogeneic Stem... | 18 Years - 60 Years | Sanofi | |
| Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma | NCT02724904 | Lymphoma | Allogeneic stem... Fludarabine Thiotepa Methotrexate | 18 Years - | Massachusetts General Hospital | |
| Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation. | NCT02017457 | Acute Myelogeno... Myelodysplastic... | Donor lymphocyt... Azacytidine | 18 Years - | University Hospital of Mont-Godinne | |
| Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients | NCT02098512 | Hodgkin Lymphom... | Brentuximab Ved... Allogeneic Stem... Reduced Intensi... | - 45 Years | New York Medical College | |
| Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma | NCT01636388 | Hodgkins Lympho... | allogeneic dono... | - 45 Years | New York Medical College | |
| Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant | NCT05982275 | Multiple Myelom... Allogeneic Stem... | CARTemis-1 | 18 Years - | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | |
| Treosulfan-based Conditioning for Transplantation in AML/MDS | NCT00491634 | Acute Myeloid L... Myelodysplastic... | treosulfan Treosulfan | 18 Years - 68 Years | Sheba Medical Center | |
| A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation | NCT01068301 | Acute Lymphobla... Acute Myeloid L... Chronic Myeloid... Myelodysplastic... Non-Hodgkin's L... | Plerixafor | - 21 Years | St. Jude Children's Research Hospital | |
| Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients | NCT00499889 | Leukemia | Imatinib Mesyla... Fludarabine (Fl... Busulfan Antithymocyte G... Tacrolimus Methotrexate Donor lymphocyt... Stem Cell Trans... | - 70 Years | M.D. Anderson Cancer Center | |
| Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations | NCT02298166 | Acute Myeloid L... | chemotherapy (M... Placebo Crenolanib Allogeneic stem... | 18 Years - | University of Ulm | |
| Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation | NCT06028828 | Allogeneic Hema... Allogeneic Stem... Hematologic Mal... | Fludarabine Melphalan Total Body Irra... | 18 Years - 70 Years | University of California, Irvine | |
| Immunoevasive Tactics Employed by Myeloid Malignancy After Allogeneic Stem Cell Transplantation | NCT03964922 | Relapse Leukemi... Allogeneic Stem... Immune Evasion,... | blood sample bone marrow sam... | 18 Years - 71 Years | Central Hospital, Nancy, France | |
| Stem Cell Transplantation for Patients With Hematologic Malignancies | NCT00152139 | Acute Lymphobla... Acute Myelocyti... Chronic Myeloid... Juvenile Myelom... Myelodysplastic... Hemoglobinuria,... Non-Hodgkin Lym... | Allogeneic Stem... Chemotherapy an... | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML | NCT02891278 | Acute Myeloid L... | Sertraline Cytosine arabin... allogeneic stem... | 18 Years - 70 Years | Columbia University | |
| CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia | NCT03882203 | Refractory Hema... Allogeneic Stem... | CLAGE-FluBu | 16 Years - 60 Years | Shanghai Jiao Tong University School of Medicine | |
| Exercise During the Allogeneic Stem Cell Transplantation | NCT00883714 | Fatigue Allogeneic Stem... | Supervised exer... Exercise Instru... | 18 Years - 70 Years | Charite University, Berlin, Germany | |
| Pasireotide in Prevention of GI Toxicity | NCT02215070 | Hematological M... | Pasireotide | 18 Years - | Duke University | |
| Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 | NCT04628026 | Acute Myeloid L... Myelodysplastic... | Venetoclax Placebo Standard chemot... Autologous stem... Allogeneic stem... | 18 Years - | University of Ulm | |
| 5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome | NCT00721214 | Myelodysplastic... | 5-azacytidine | 18 Years - 70 Years | Virginia Commonwealth University | |
| 5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS) | NCT01404741 | Myelodysplastic... Chronic Myelomo... | allogeneic stem... 5-azacytidine u... | 55 Years - 70 Years | Universitätsklinikum Hamburg-Eppendorf | |
| A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation | NCT06297629 | Allogeneic Stem... | ASTX727 Donor Lymphocyt... | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation | NCT01068301 | Acute Lymphobla... Acute Myeloid L... Chronic Myeloid... Myelodysplastic... Non-Hodgkin's L... | Plerixafor | - 21 Years | St. Jude Children's Research Hospital | |
| Stem Cell Transplantation for Patients With Hematologic Malignancies | NCT00152139 | Acute Lymphobla... Acute Myelocyti... Chronic Myeloid... Juvenile Myelom... Myelodysplastic... Hemoglobinuria,... Non-Hodgkin Lym... | Allogeneic Stem... Chemotherapy an... | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Creation of Bone Marrow Microenvironment for Treatment of Myelodysplastic Syndrome (MDS) in Conjunction With Allogeneic Stem Cell Transplantation | NCT00148980 | Myelodysplastic... Myelofibrosis | DBM for creatio... | 18 Years - | Hadassah Medical Organization | |
| Bisantrene for Relapsed /Refractory AML | NCT03820908 | Acute Myelogeno... Allogeneic Stem... | Bisantrene | 18 Years - | Sheba Medical Center | |
| Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion | NCT00966810 | Philadelphia Ch... | Stem cell trans... | 18 Years - 65 Years | Rambam Health Care Campus | |
| CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia | NCT03882203 | Refractory Hema... Allogeneic Stem... | CLAGE-FluBu | 16 Years - 60 Years | Shanghai Jiao Tong University School of Medicine | |
| Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT) | NCT02169505 | Lymphoma | Brentuximab Ved... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies | NCT00841724 | Hematological M... | Fludarabine, Bu... | 18 Years - 65 Years | Nantes University Hospital | |
| Randomized Clinical Study Assessing Haplo vs. URD in AML | NCT04067180 | Acute Myeloid L... | allogeneic stem... allogeneic stem... | 18 Years - | Karolinska Institutet | |
| 5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS) | NCT01404741 | Myelodysplastic... Chronic Myelomo... | allogeneic stem... 5-azacytidine u... | 55 Years - 70 Years | Universitätsklinikum Hamburg-Eppendorf | |
| Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies | NCT00048737 | Lymphoma Leukemia | Zevalin Radioim... Rituximab Fludarabine Cyclophosphamid... Allogeneic Stem... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma | NCT01969942 | Ewing Sarcoma | allogeneic stem... Clyclophosphami... Fludarabina Busulfan Melphalan | - 30 Years | University of Louisville | |
| Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies. | NCT00890500 | Hematologic Mal... Allogeneic Stem... | Fludarabine Melphalan Antithymocyte G... Sirolimus Tacrolimus | 18 Years - 65 Years | Fate Therapeutics | |
| Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation | NCT00593645 | Myelodysplastic... Acute Myeloid L... | Clofarabine Cytarabine Thymoglobulin Stem cell infus... | 18 Years - | Washington University School of Medicine | |
| TevaGastrim for Stem Cell Mobilization Sibling Donors | NCT01542944 | Acute Myeloid L... Myelodysplastic... | TevaGastrim | 18 Years - 70 Years | Sheba Medical Center | |
| T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation | NCT00306332 | Leukemia, Myelo... Leukemia, Lymph... Myelodysplastic... Leukemia, Myelo... Lymphoma | T-cell and B-ce... | 18 Years - 65 Years | Radboud University Medical Center | |
| Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells | NCT01092026 | Allogeneic Stem... | cord blood tran... | 15 Years - 60 Years | Universitair Ziekenhuis Brussel | |
| Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | NCT00857389 | Stem Cell Trans... Leukemia Lymphoma | Thiotepa Clofarabine Busulfan Allogeneic Stem... Thymoglobulin (... G-CSF (Filgrast... Tacrolimus Methotrexate Cyclophosphamid... Mesna | - 60 Years | M.D. Anderson Cancer Center | |
| Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) | NCT02410551 | Myeloproliferat... | Pacritinib Busulfan Questionnaires Phone Calls Allogeneic Stem... Fludarabine | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| An Evaluation of the Effect of 'Open Window' on Psychological Well-being and Experience of Stem Cell Transplantation | NCT00348959 | Hematological M... | 'Open Window' P... | 16 Years - | St. James's Hospital, Ireland | |
| Treatment of Acute Leukemia Relapse After Allotransplantation | NCT01369368 | Acute Myeloid L... | Combined use of... | 18 Years - 90 Years | University of Bergen | |
| Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation | NCT02312102 | Myelodysplastic... Acute Myeloid L... | Lenalidomide Velcade | 18 Years - | Massachusetts General Hospital | |
| Haploidentical Peripheral Blood Stem Cell Transplantation for Acute Leukemia | NCT03756675 | Acute Leukemia | haplotype PBSCT | 2 Years - 60 Years | Peking University People's Hospital | |
| Ruxolitinib + Allogeneic Stem Cell Transplantation in AML | NCT03286530 | Acute Myeloid L... Acute Myeloid L... Allogeneic Stem... | Ruxolitinib | 60 Years - 80 Years | Massachusetts General Hospital | |
| Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG) | NCT00266136 | Acute Myeloid L... | Cytarabine Thioguanine Daunorubicin Cyclophosphamid... G-CSF Autologous stem... Allogeneic stem... | 16 Years - | University Hospital Muenster | |
| Cognition in Allogeneic Stem Cell Transplanted Patients and Sports | NCT02533947 | Allogeneic Stem... Exercise Interv... | Exercise Control | 18 Years - 75 Years | Universitätsklinikum Hamburg-Eppendorf | |
| Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma | NCT02059239 | Hodgkin's Lymph... Non-Hodgkin's L... | Bendamustine Carmustine Etoposide Melphalan Cytarabine Alemtuzumab Autologous Stem... Allogeneic Stem... Rituximab | 18 Years - | Weill Medical College of Cornell University | |
| Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) | NCT03645824 | Myelofibrosis | Pacritinib | 18 Years - 70 Years | Stichting Hemato-Oncologie voor Volwassenen Nederland | |
| Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation | NCT01517347 | Leukemia | Interleukin-2 | 15 Years - 65 Years | Peking University People's Hospital | |
| T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies | NCT02659943 | Lymphoma, B-Cel... Lymphoma, Non-h... | Anti-cluster of... Cyclophosphamid... Fludarabine | 18 Years - 73 Years | National Institutes of Health Clinical Center (CC) | |
| 5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome | NCT00721214 | Myelodysplastic... | 5-azacytidine | 18 Years - 70 Years | Virginia Commonwealth University | |
| Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma | NCT02724904 | Lymphoma | Allogeneic stem... Fludarabine Thiotepa Methotrexate | 18 Years - | Massachusetts General Hospital | |
| GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia | NCT02799147 | Leukemia, Acute... Acute Myeloid L... Mixed-Lineage A... | Allogeneic stem... Fludarabine mon... Busulfan Bendamustine | 18 Years - 60 Years | St. Petersburg State Pavlov Medical University | |
| Dose-range Finding Treosulfan-based Conditioning | NCT01063647 | Hematological M... | Treosulfan Treosulfan Treosulfan | 18 Years - | medac GmbH | |
| Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion | NCT00966810 | Philadelphia Ch... | Stem cell trans... | 18 Years - 65 Years | Rambam Health Care Campus | |
| Ruxolitinib + Allogeneic Stem Cell Transplantation in AML | NCT03286530 | Acute Myeloid L... Acute Myeloid L... Allogeneic Stem... | Ruxolitinib | 60 Years - 80 Years | Massachusetts General Hospital | |
| Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation | NCT01087294 | Leukemia, B-cel... Lymphoma, Hodgk... Lymphoma, Non-h... Lymphoma, B-Cel... | Allogeneic stem... Anti-CD19-chime... Leukapheresis | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG) | NCT00266136 | Acute Myeloid L... | Cytarabine Thioguanine Daunorubicin Cyclophosphamid... G-CSF Autologous stem... Allogeneic stem... | 16 Years - | University Hospital Muenster | |
| Physical Exercise Therapy vs Relaxation in Allogeneic Stem Cell Transplantation (PETRA) | NCT01374399 | Allogeneic Stem... | exercise and re... | 18 Years - | German Cancer Research Center | |
| Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) | NCT05443854 | Sepsis Septic Shock Hematologic Mal... Tumor Allogeneic Stem... | Aminoglycosides... Lack of protect... No systematic a... Protective isol... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Ruxolitinib + Allogeneic Stem Cell Transplantation in AML | NCT03286530 | Acute Myeloid L... Acute Myeloid L... Allogeneic Stem... | Ruxolitinib | 60 Years - 80 Years | Massachusetts General Hospital | |
| Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) | NCT03645824 | Myelofibrosis | Pacritinib | 18 Years - 70 Years | Stichting Hemato-Oncologie voor Volwassenen Nederland | |
| IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML | NCT06418776 | Refractory Acut... Early Relapses ... | Intensive thera... Low intensity t... | 18 Years - | National Research Center for Hematology, Russia | |
| CIBMTR Research Database | NCT01166009 | Autologous Stem... Allogeneic Stem... Solid Tumors Blood Cancers CAR-T Gene Therapy Non-malignant D... | - | Center for International Blood and Marrow Transplant Research | ||
| A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation | NCT06297629 | Allogeneic Stem... | ASTX727 Donor Lymphocyt... | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation | NCT00593645 | Myelodysplastic... Acute Myeloid L... | Clofarabine Cytarabine Thymoglobulin Stem cell infus... | 18 Years - | Washington University School of Medicine | |
| AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion | NCT04099966 | Acute Leukemia Severe Aplastic... Non-hodgkin Lym... Hodgkin Lymphom... Kostmann Diamond Blackfa... Amegakaryocytic... Sickle Cell Dis... Beta-Thalassemi... | alpha beta depl... | 1 Day - 30 Years | New York Medical College | |
| Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma | NCT02724904 | Lymphoma | Allogeneic stem... Fludarabine Thiotepa Methotrexate | 18 Years - | Massachusetts General Hospital | |
| Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia | NCT01020539 | Acute Myelogeno... Myelodysplastic... Juvenile Myelom... | Fludarabine Busulfan GVHD Prophylaxi... Gemtuzumab Ozog... Anti-Thymocyte ... Isotretinoin | 1 Month - 30 Years | Columbia University | |
| HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies | NCT00145626 | Acute Myeloid L... Acute Lymphocyt... Myelodysplasia Chronic Myeloid... Histiocytosis | Chemotherapy an... Miltenyi Biotec... Allogeneic stem... | - 24 Months | St. Jude Children's Research Hospital | |
| Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia | NCT01020539 | Acute Myelogeno... Myelodysplastic... Juvenile Myelom... | Fludarabine Busulfan GVHD Prophylaxi... Gemtuzumab Ozog... Anti-Thymocyte ... Isotretinoin | 1 Month - 30 Years | Columbia University | |
| Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma | NCT02059239 | Hodgkin's Lymph... Non-Hodgkin's L... | Bendamustine Carmustine Etoposide Melphalan Cytarabine Alemtuzumab Autologous Stem... Allogeneic Stem... Rituximab | 18 Years - | Weill Medical College of Cornell University | |
| IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation | NCT04628338 | Myelodysplastic... Myeloid Leukemi... Allogeneic Stem... | IFN-γ (interfer... | 18 Years - | University of Pittsburgh | |
| Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells | NCT01092026 | Allogeneic Stem... | cord blood tran... | 15 Years - 60 Years | Universitair Ziekenhuis Brussel | |
| Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL | NCT06175702 | Lymphoblastic L... Philadelphia-Po... Adult ALL | Vincristine Dexamethasone Imatinib Cytarabine Mercaptopurine Methotrexate Ponatinib allogeneic stem... Total body irra... Cyclophosphamid... Fludarabine | 18 Years - | PETHEMA Foundation | |
| IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation | NCT04628338 | Myelodysplastic... Myeloid Leukemi... Allogeneic Stem... | IFN-γ (interfer... | 18 Years - | University of Pittsburgh | |
| Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia | NCT04232241 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... | Allogeneic Stem... | 18 Years - 70 Years | Universitätsklinikum Hamburg-Eppendorf | |
| Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD | NCT06093334 | Acute Lymphobla... Hodgkin Disease Allogeneic Stem... | Low-field magne... Cardiopulmonary... Pulmonary testi... Blood sample | 5 Years - 17 Years | University of Erlangen-Nürnberg Medical School | |
| TevaGastrim for Stem Cell Mobilization Sibling Donors | NCT01542944 | Acute Myeloid L... Myelodysplastic... | TevaGastrim | 18 Years - 70 Years | Sheba Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
